

Author: Jacob S.
Publisher: Adis International
ISSN: 0012-6667
Source: Drugs, Vol.64, Iss.11, 2004-01, pp. : 1263-1263
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content




By Colla L. La
Clinical Pharmacokinetics, Vol. 48, Iss. 6, 2009-06 ,pp. :




Bevacizumab and hypertension: a Catch-22?
Reactions Weekly, Vol. 1, Iss. 1292, 2010-01 ,pp. :


Gene therapy for pulmonary hypertension?
Inpharma, Vol. 1, Iss. 1231, 2000-01 ,pp. :